drugset / Trial / NCT04214808

To Evaluate the Pharmacokinetics and Safety of AD-208

NCT04214808

Phase 1 Completed 24 enrolled Addpharma Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

To evaluate pharmacokinetics and safety of AD-208.

Timeline

Start
2020-01-03
Primary completion
2020-02-04
Completion
2020-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dutasteride Small molecule 0.2 mg
Subject Dutasteride Small molecule 0.5 mg

Indications